查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1497603

急性護理綜合症檢測市場：按疾病類型、目標、樣本類型和最終用戶 - 2024-2030 年全球預測

Acute Care Syndromic Testing Market by Disease Type (Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases), Target (Bacteria, Fungi, Parasites), Sample Type, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年急性醫學症候群檢測市場規模為34億美元，預計2024年將達37.4億美元，2030年將達66.3億美元，複合年成長率為9.99%。

急性護理綜合症測試是指在醫療機構中使用的快速診斷過程，透過同時測試多種可能的原因來確定有症狀患者的臨床症狀的原因。即時聚合酵素鏈鎖反應(PCR) 可用於定性檢測和識別病毒、細菌、真菌和寄生蟲病原體。這種方法在急診室和加護病房等急診護理環境中尤其重要，因為在這些環境中，即時決策至關重要。我們使用的測試組合涵蓋了與特定臨床症候群相關的病原體和病症，例如呼吸道疾病和胃腸道感染疾病。包括多重抗藥性病原體在內的感染疾病的流行增加了對快速綜合症檢測的需求。此外，政府改善醫療基礎設施和促進先進診斷系統採用的措施也促進了市場成長。然而，假陽性和陰性的發生率以及某些綜合症測試缺乏足夠的報銷可能會阻礙急性護理綜合症測試的採用。此外，技術挑戰和檢測有限數量微生物病原體的能力也是產業發展的障礙。然而，大公司正在尋求開發更廣泛的組合，可以在一次測試中檢測多種病原體。臨床和醫學微生物學的研究舉措和進展可以提高急性護理症候群測試工具的性能和準確性。此外，人工智慧/機器學習、資料分析技術和計算生物學策略等先進數位技術的整合可以為該行業提供新的成長途徑。

主要市場統計
基準年[2023] 34億美元
預測年份 [2024] 37.4億美元
預測年份 [2030] 66.3億美元
複合年成長率（%） 9.99%

區域洞察

以美國和加拿大為中心的美洲地區擁有強大的醫療基礎設施和數位化醫療框架，極大地推動了醫院和診所採用急性護理綜合症檢測。在其他活動中，疾病管制與預防美國(CDC) 和其他聯邦機構正在積極鼓勵開發快速綜合症檢測方法。醫療支付者和醫院是重要的客戶，他們的購買行為反映了對能夠快速提供結果並支持抗菌藥物管理的全面解決方案的偏好。歐盟強調遵守與醫療保健產業相關的嚴格法規。此外，學術機構、主要企業和研究機構之間的密切合作正在推動診斷和症候群檢測領域的創新和改進。抗菌素抗藥性的增加也推動了對先進診斷工具的需求。在亞太地區，對醫療改革和政府舉措的日益關注以及擴大先進醫療服務和設施的資助是推動急性護理綜合症檢測採用的關鍵因素。來自韓國、印度和中國的參與者正在與診斷測試實驗室合作，擴大急性護理症候群測試的普及。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在急性護理症候群測試市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對急性護理綜合症檢測市場中供應商的現狀進行深入而詳細的評估。對供應商貢獻的徹底比較和分析可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在急性護理綜合症檢測市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病發生率增加
      • 使用症狀測試檢測抗菌藥物抗藥性
      • 政府努力擴大性行為感染傳染病的治療和診斷
    • 抑制因素
      • 假陽性和陰性的發生率以及污染的可能性
    • 機會
      • 將綜合症測試納入管理計劃的努力
      • 臨床微生物學的進步改進了檢測策略
    • 任務
      • 急性護理綜合症檢測方法的技術局限性
  • 市場區隔分析
    • 疾病類型：污染程度的增加和氣候模式的變化導致呼吸道疾病的盛行率急劇增加
    • 目標：需要及時、快速診斷急診環境中的細菌感染疾病
    • 樣本類型：利用血液樣本促進感染疾病和敗血症的檢測
    • 最終用戶：增加私人投資和政府努力升級醫院基礎設施
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 急性醫學症狀檢測市場：依疾病類型

  • 消化系統疾病
  • 泌尿系統疾病
  • 呼吸系統疾病
  • 熱帶疾病

第7章 急性醫學症狀檢測市場目標

  • 細菌
  • 菌類
  • 寄生蟲
  • 病毒

第8章依樣本類型分類的急診症候群檢測市場

  • 生物體液
  • 血
  • 凳子
  • 棉花棒
  • 尿

第9章 急性醫學症候群檢測市場：依最終使用者分類

  • 臨床和診斷實驗室
  • 醫院
  • 研究/學術機構

第10章美洲急性醫學症檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區急性醫學症候群檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的急性醫學症候群檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准針對 COVID-19 的家庭抗原測試
    • 拜登政府提供美國家庭免費新冠病毒檢測，向國內製造商投資6億美元
    • NIH 推出居家測試作為 COVID-19遠端醫療計劃試點
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-5A3042B3D68E

[192 Pages Report] The Acute Care Syndromic Testing Market size was estimated at USD 3.40 billion in 2023 and expected to reach USD 3.74 billion in 2024, at a CAGR 9.99% to reach USD 6.63 billion by 2030.

Acute care syndromic testing refers to the rapid diagnostic process used in healthcare settings to identify the cause of a symptomatic patient's clinical symptoms by testing for multiple possible causes simultaneously. It facilitates qualitative detection and identification of viral, bacterial, fungal, and parasitic pathogens using real-time polymerase chain reaction (PCR). This approach is particularly significant in acute care settings where time-sensitive decisions are crucial, such as emergency departments or intensive care units. It employs panels of tests that cover a range of pathogens or conditions associated with a particular clinical syndrome, such as respiratory illness or gastrointestinal infection. The rise in infectious disease prevalence, including multi-drug-resistant pathogens, drives the need for rapid syndromic testing. Furthermore, government initiatives to improve medical infrastructure and stimulate the adoption of advanced diagnostics systems contribute to market growth. However, incidences of false positives and negatives and a lack of adequate reimbursements for certain syndromic tests can impede the adoption of acute care syndromic testing. Additionally, technical challenges and the ability to detect a limited number of microbial pathogens pose hurdles to the growth of the industry. However, key players are exploring the development of broader-ranging panels that can detect multiple pathogens in a single test. Research initiatives and advancements in clinical and medical microbiology can improve the performance and accuracy of acute care syndromic testing tools. Furthermore, the integration of advanced digital technologies such as AI/ML, data analysis technologies, and computational biology strategies can create new avenues of growth for the industry.

KEY MARKET STATISTICS
Base Year [2023] USD 3.40 billion
Estimated Year [2024] USD 3.74 billion
Forecast Year [2030] USD 6.63 billion
CAGR (%) 9.99%

Regional Insights

The Americas region, particularly the US and Canada, boasts a robust healthcare infrastructure and digitalized healthcare framework, significantly driving the adoption of acute care syndromic testing in hospitals and clinics. Additionally, the Centers for Disease Control and Prevention (CDC) and other federal bodies actively encourage the development of rapid syndromic testing methods. Health insurers and hospitals are significant customers, and their purchasing behavior reflects a preference for integrated solutions that can provide quick results and aid in antimicrobial stewardship. The EU puts emphasis on compliance with stringent regulations pertaining to the healthcare sector. Additionally, strong collaborations between academic institutions, key players, and research institutes have led to innovations and improvements in the field of diagnostics and syndromic testing. Increasing antimicrobial resistance has also propelled the need for advanced diagnostics tools. In the APAC region, growing focus on healthcare reform and government initiatives and funds to expand access to advanced medical services and facilities are key factors leading to the adoption of acute care syndromic testing. Players in South Korea, India, and China are collaborating with diagnostic testing laboratories to expand the spread of acute care syndromic testing.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Acute Care Syndromic Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising incidences of infectious disease outbreaks
      • Utilization of syndromic tests for detecting antimicrobial resistance
      • Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
    • Market Restraints
      • Incidences of false positives and false negatives and chances of contamination
    • Market Opportunities
      • Efforts to include syndromic testing under stewardship programs
      • Advancements in clinical microbiology leading to improved testing strategies
    • Market Challenges
      • Technical limitations of acute care syndromic testing methods
  • Market Segmentation Analysis
    • Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
    • Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
    • Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
    • End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acute Care Syndromic Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acute Care Syndromic Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Clears COVID-19 Home Antigen Test

The U.S. Food and Drug Administration (FDA) officially cleared ACON Laboratories' Flowflex COVID-19 Antigen Home Test for over-the-counter sales. This antigen test, which initially received Emergency Use Authorization in 2021, stands out as the second home diagnostic for COVID-19 to transition through a standard premarket evaluation by the FDA, marking a significant milestone. This development underscores the expansion of accessible testing options for the detection of COVID-19 for the public, including minors. [Published On: 2023-11-09]

Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers

The United States Department of Health and Human Services (HHS) confirmed its intent to combat the ongoing challenge posed by COVID-19 by providing American households with no-cost testing kits. The HHS has also unveiled an ambitious strategy, allocating USD 600 million to bolster the production capabilities of twelve domestic testing manufacturers, ensuring a robust response to the pandemic through the end of 2023. This strategic move underscores the continuing effort to keep citizens safe and well-informed amidst the evolving health crisis. [Published On: 2023-09-23]

NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program

The U.S. National Institutes of Health, in partnership with the Administration for Strategic Preparedness and Response, has rolled out an innovative Home Test to Treat program, announced previously by the White House. This virtual community health initiative seeks to offer complimentary COVID-19 health amenities to designated communities, including at-home rapid tests, telehealth consultations, and treatment options. Through this program, individuals who test positive for COVID-19 using at-home tests are eligible to receive antiviral medications, enhancing their chances of averting serious illness, hospitalization, or death. [Published On: 2023-01-05]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acute Care Syndromic Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Acute Care Syndromic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Applied BioCode, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, BIOHM Health LLC, bioMerieux SA, Curetis GmbH b y OpGen, Inc, CVS Health, Danaher Corporation, DiaSorin S.p.A, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Genetic Signatures Ltd., Hologic Inc., Luminex Corporation, Microbiologics, Inc., Pfizer, Inc., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.

Market Segmentation & Coverage

This research report categorizes the Acute Care Syndromic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Gastrointestinal Diseases
    • Genitourinary Diseases
    • Respiratory Diseases
    • Tropical Diseases
  • Target
    • Bacteria
    • Fungi
    • Parasites
    • Viruses
  • Sample Type
    • Biofluids
    • Blood
    • Stool
    • Swabs
    • Urine
  • End User
    • Clinical & Diagnostic Laboratories
    • Hospitals
    • Research & Academic Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious disease outbreaks
      • 5.1.1.2. Utilization of syndromic tests for detecting antimicrobial resistance
      • 5.1.1.3. Government initiatives to expand treatment and diagnosis of sexually transmitted diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of false positives and false negatives and chances of contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Efforts to include syndromic testing under stewardship programs
      • 5.1.3.2. Advancements in clinical microbiology leading to improved testing strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations of acute care syndromic testing methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing pollution levels and changing climate patterns leading to a surge in the prevalence of respiratory diseases
    • 5.2.2. Target: Need for timely and rapid diagnosis of bacterial infections in acute care settings
    • 5.2.3. Sample Type: Utilization of blood samples to facilitate detection of infections and sepsis
    • 5.2.4. End User: Expanding private investments and government initiatives to upgrade hospital infrastructure
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Acute Care Syndromic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Gastrointestinal Diseases
  • 6.3. Genitourinary Diseases
  • 6.4. Respiratory Diseases
  • 6.5. Tropical Diseases

7. Acute Care Syndromic Testing Market, by Target

  • 7.1. Introduction
  • 7.2. Bacteria
  • 7.3. Fungi
  • 7.4. Parasites
  • 7.5. Viruses

8. Acute Care Syndromic Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Biofluids
  • 8.3. Blood
  • 8.4. Stool
  • 8.5. Swabs
  • 8.6. Urine

9. Acute Care Syndromic Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Clinical & Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Research & Academic Institutions

10. Americas Acute Care Syndromic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Care Syndromic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Care Syndromic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Clears COVID-19 Home Antigen Test
    • 13.3.2. Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers
    • 13.3.3. NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ACUTE CARE SYNDROMIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACUTE CARE SYNDROMIC TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE CARE SYNDROMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GENITOURINARY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GENITOURINARY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY FUNGI, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRUSES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRUSES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BIOFLUIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BIOFLUIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BLOOD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STOOL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STOOL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SWABS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY URINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 283. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 291. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 299. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 307. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 315. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TARGET, 2024-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. SAUDI ARABIA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA ACU